ATE259825T1 - Hemihydrat von 16.alpha.-bromoepiandrosterone - Google Patents

Hemihydrat von 16.alpha.-bromoepiandrosterone

Info

Publication number
ATE259825T1
ATE259825T1 AT00918365T AT00918365T ATE259825T1 AT E259825 T1 ATE259825 T1 AT E259825T1 AT 00918365 T AT00918365 T AT 00918365T AT 00918365 T AT00918365 T AT 00918365T AT E259825 T1 ATE259825 T1 AT E259825T1
Authority
AT
Austria
Prior art keywords
bromoepiandrosterone
hemihydrate
alpha
Prior art date
Application number
AT00918365T
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Carvalho Dos Anjos Luis Dan De
William Heggie
Patrick T Prendergast
Christopher L Reading
Krupakar Paul Thadikonda
Russell Neil Vernon
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Application granted granted Critical
Publication of ATE259825T1 publication Critical patent/ATE259825T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00918365T 1999-03-23 2000-03-23 Hemihydrat von 16.alpha.-bromoepiandrosterone ATE259825T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US14002899P 1999-06-16 1999-06-16
US41490599A 1999-10-08 1999-10-08
US16404899P 1999-11-08 1999-11-08
PCT/US2000/007883 WO2000056757A1 (en) 1999-03-23 2000-03-23 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone

Publications (1)

Publication Number Publication Date
ATE259825T1 true ATE259825T1 (de) 2004-03-15

Family

ID=27494614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918365T ATE259825T1 (de) 1999-03-23 2000-03-23 Hemihydrat von 16.alpha.-bromoepiandrosterone

Country Status (22)

Country Link
EP (1) EP1163256B1 (de)
JP (1) JP2002540119A (de)
KR (2) KR20070007394A (de)
CN (1) CN1243767C (de)
AP (1) AP2001002285A0 (de)
AT (1) ATE259825T1 (de)
AU (1) AU781997B2 (de)
BR (1) BR0009476A (de)
CA (1) CA2365081A1 (de)
CZ (1) CZ20013420A3 (de)
DE (1) DE60008353T2 (de)
DK (1) DK1163256T3 (de)
ES (1) ES2215631T3 (de)
HK (1) HK1046002B (de)
HU (1) HUP0203429A3 (de)
IL (1) IL144916A0 (de)
NO (2) NO320801B1 (de)
NZ (1) NZ513803A (de)
OA (1) OA11850A (de)
PT (1) PT1163256E (de)
RU (2) RU2417792C2 (de)
WO (1) WO2000056757A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
JP2004537506A (ja) * 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症を治療するためのある種のステロイドの使用
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
AU2004308806B9 (en) * 2003-12-26 2010-01-28 Nissan Chemical Industries, Ltd. Neutrophilia inhibitor
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
CN118976020A (zh) * 2018-06-01 2024-11-19 雀巢产品有限公司 膳食丁酸盐（酯）
US10836788B2 (en) * 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
JP7814306B2 (ja) * 2019-12-05 2026-02-16 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 食品用ブチレート
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
ES8706717A1 (es) * 1983-08-02 1987-07-01 Research Corp Metodo de preparar esteroides
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Also Published As

Publication number Publication date
DE60008353D1 (de) 2004-03-25
ES2215631T3 (es) 2004-10-16
AU3919000A (en) 2000-10-09
HK1046002B (zh) 2006-10-20
CN1243767C (zh) 2006-03-01
HUP0203429A2 (hu) 2003-01-28
RU2001128881A (ru) 2003-09-27
RU2417792C2 (ru) 2011-05-10
RU2006133273A (ru) 2008-03-27
OA11850A (en) 2006-03-06
DE60008353T2 (de) 2005-09-08
CZ20013420A3 (cs) 2002-04-17
WO2000056757A1 (en) 2000-09-28
CA2365081A1 (en) 2000-09-28
BR0009476A (pt) 2002-02-19
IL144916A0 (en) 2002-06-30
NZ513803A (en) 2004-06-25
EP1163256B1 (de) 2004-02-18
KR20020003217A (ko) 2002-01-10
HK1046002A1 (en) 2002-12-20
KR20070007394A (ko) 2007-01-15
JP2002540119A (ja) 2002-11-26
CN1355809A (zh) 2002-06-26
AP2001002285A0 (en) 2001-12-31
AU781997B2 (en) 2005-06-23
DK1163256T3 (da) 2004-06-28
NO20014588D0 (no) 2001-09-21
KR100717897B1 (ko) 2007-05-14
NO20014588L (no) 2001-11-21
RU2295534C2 (ru) 2007-03-20
HUP0203429A3 (en) 2004-07-28
EP1163256A1 (de) 2001-12-19
NO320801B1 (no) 2006-01-30
PT1163256E (pt) 2004-07-30
NO20056167L (no) 2001-11-21

Similar Documents

Publication Publication Date Title
DE122012000017I1 (de) Neuartige form von s-omeprazol.
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE69932650D1 (de) Zementierkopf
DK0975638T3 (da) Sidekædemodificerede epothiloner
EP1235651A4 (de) Zementzusammensetzung
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
ID29149A (id) Komposisi adjuvan
ID24458A (id) Modifikasi rheologi in-sito poliolefin
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
DE69931821D1 (de) Wärmehärtbare pulverlack-zusammensetzung
DE69943245D1 (de) Gaserzeugende zusammensetzung
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
NO20002555D0 (no) Skjøt
DE69804218D1 (de) Zementzusammensetzung
FR2791258B1 (fr) Composition amincissante
PT964867E (pt) Antagonistas da taquicinima
FI19992609L (fi) Uusi koostumus
DE59711737D1 (de) Gewölbtes Metall-Keramik-Substrat
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
DE60007360D1 (de) Amorphe modifikation von torasemid
ID27329A (id) Komposisi penghambat
ID30381A (id) Penggunaan arilalkanoilpiridazina
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
ES1042496Y (es) "pilona sumible".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163256

Country of ref document: EP

REN Ceased due to non-payment of the annual fee